Shilpa Biologicals commissioned an integrated ADC drug substance GMP manufacturing facility in India, with full operations and GMP qualification protocols underway. The build is designed to meet global regulatory approval standards across the U.S., EMA, and other health authorities. Management said the facility strengthens Shilpa’s high-potency capabilities and aims to serve global biotech and pharma partners seeking outsourced ADC drug substance manufacturing. The move supports contract manufacturing growth as ADC pipelines continue to expand worldwide.